{"entity":{"id":"nct05768178","kind":"trial","name":"DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.","aka":["DETERMINE"],"tldr":"A phase 2/3 trial of vemurafenib and cobimetinib in colorectal cancer, run by Cancer Research UK, now recruiting.","summary":"DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers. is a phase 2/3, interventional study registered as NCT05768178 by Cancer Research UK, with a registry enrolment figure of 30 participants, started 2023-03-01 and due to reach its primary completion in 2029-10. Interventions recorded: Vemurafenib; Cobimetinib. Conditions listed: Haematological Malignancy; Melanoma; Thyroid Cancer, Papillary; Ovarian Neoplasms; Colorectal Neoplasms; Laryngeal Neoplasms; Carcinoma, Non-Small-Cell Lung; Glioma; Multiple Myeloma; Erdheim-Chester Disease; Thyroid Carcinoma, Anaplastic; Solid Tumour. Primary outcome: Objective Response (OR); Durable Clinical Benefit (DCB). Colorectal eligibility wording from the registry: \"Patients with QTcF (Corrected QT interval by Fridericia) at screening of \\>450 ms for males and \\>470 ms for females measured on triplicate ECG (if 1/3 readings show \\>450/470 ms then patient is ineligible)\". Sites: United Kingdom. United Kingdom sites listed: 16. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT05768178","url":"https://clinicaltrials.gov/study/NCT05768178"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","colon-cancer"],"sections":[],"technologies":["kinase-inhibitors"],"targets":[],"drugs":["vemurafenib","cobimetinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["UK sites (registry): Belfast City Hospital (Belfast); University Hospital Birmingham (Birmingham); Bristol Haematology and Oncology Centre (Bristol); Addenbrooke's Hospital (Cambridge); Velindre Cancer Centre (Cardiff); Western General Hospital (Edinburgh); The Beatson Hospital (Glasgow); Leicester Royal Infirmary (Leicester); University College London Hospital (London); Guy's Hospital (London); The Christie Hospital (Manchester); Clatterbridge Cancer Centre (Metropolitan Borough of Wirral) and 4 more."],"nct":"NCT05768178","phase":"2/3","setting":"DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial): An Umbrella-Basket Platform Trial to Evaluate the Efficacy of Targeted Therapies in Rare Adult, Paediatric and Teenage/Young Adult (TYA) Cancers With Actionable Genomic Alterations, Including Common Cancers With Rare Actionable Alterations.","sponsor":"Cancer Research UK","enrolled":30,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05768178/","neighbours":{"cancer":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"cobimetinib","kind":"drug","name":"Cobimetinib","route":"/drugs/cobimetinib/"},{"id":"vemurafenib","kind":"drug","name":"Vemurafenib","route":"/drugs/vemurafenib/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}